Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Has Consensus Target Price of $11.50

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has been given an average recommendation of “Buy” by the eleven research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $11.50.

Several equities research analysts have recently commented on CATX shares. Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, September 15th. BMO Capital Markets set a $11.00 target price on shares of Perspective Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, August 18th. BTIG Research reiterated a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a report on Wednesday. Bank of America reduced their price target on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. Finally, William Blair began coverage on shares of Perspective Therapeutics in a report on Friday, September 18th. They issued an “outperform” rating for the company.

Hedge Funds Weigh In On Perspective Therapeutics

Several institutional investors have recently modified their holdings of the business. Commodore Capital LP acquired a new position in Perspective Therapeutics in the 1st quarter worth $26,424,000. Avidity Partners Management LP raised its stake in shares of Perspective Therapeutics by 88.4% in the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after purchasing an additional 2,839,266 shares during the period. Affinity Asset Advisors LLC lifted its holdings in shares of Perspective Therapeutics by 954.9% in the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock valued at $13,196,000 after purchasing an additional 2,864,582 shares in the last quarter. Spruce Street Capital LP bought a new stake in shares of Perspective Therapeutics in the first quarter valued at about $10,955,000. Finally, Yu Fan acquired a new position in shares of Perspective Therapeutics during the first quarter worth about $4,401,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock opened at $2.66 on Wednesday. The firm has a 50 day simple moving average of $2.94 and a 200 day simple moving average of $3.40. Perspective Therapeutics has a fifty-two week low of $1.96 and a fifty-two week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%. On average, analysts expect that Perspective Therapeutics will post -0.98 EPS for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc is a clinical-stage radiopharmaceutical biotechnology company developing precision-targeted alpha therapies for cancer. The company’s approach combines tumor-targeting molecules with radioactive isotopes to deliver highly focused radiation to cancer cells while limiting exposure to surrounding healthy tissue.

Perspective’s proprietary VMT platform is designed to support both diagnostic imaging and therapeutic applications. Its lead programs include VMT-α-NET, an investigational therapy targeting somatostatin receptor 2 for patients with neuroendocrine tumors, and VMT01, an investigational program targeting melanocortin 1 receptor-expressing cancers, including certain metastatic melanomas.